Advagene today announced the successful completion of dosing for all subjects in its Phase II clinical trial of AD17002. AD17002 is an innovative mucosal immunomodulator developed for the treatment of moderate-to-severe eosinophilic asthma. The trial has now officially advanced to the final data tracking and analysis stage. The company expects to unblind the data and release the final clinical trial results in the first quarter of 2027. This milestone highlights Advagene's strong execution capabilities as it continues to advance AD17002 toward global licensing and providing patients with a safer, more effective treatment option.